Suzanne Edavettal
Vice President, Research & Head, Protein Therapeutics Amgen
Suzanne Edavettal is Vice President of Research, Protein Therapeutics at Amgen, where she leads discovery and optimization efforts for innovative large molecule and protein based medicines. With deep expertise in biologics discovery, protein engineering, and large molecule research strategy, Suzanne plays a central role in advancing Amgen’s next generation of therapeutic proteins. She has held progressive scientific leadership roles across biologics optimization and discovery and brings more than two decades of experience spanning Amgen, Johnson & Johnson, Bristol Myers Squibb, and Merck.
Seminars
Tuesday 13th October 2026
Panel Discussion: Contextualizing the Current Status of Novel ADC Design & Development to Ensure Future ADC Success & Differentiated Patient Impact
8:00 am
- Evaluating the landscape of ADC therapies one year on: Is the field pursuing the right amount of innovation to secure the next wave of ADCs beyond Topo1?
- Delving into payload mechanisms and non-traditional ADC design: What avenues of innovation are showing promise and what needs to be demonstrated?
- Assessing hurdles and opportunities to achieve differentiated ADC clinical profiles and patient impact in crowded oncology indications
- Peering into the crystal ball: Debating the future direction of the ADC field and pioneering future possibilities
